Company 3-D Matrix, Ltd.

Equities

7777

JP3410730000

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 11:30:00 30/04/2024 am IST			5-day change	1st Jan Change
120 ^JPY	+0.84%		+1.69%	-14.29%

04/04	3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.	CI
19/03	3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.	CI

3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.

Number of employees: 108

JPY in Million	2022	Weight	2023	Weight	Delta
Medical Products 100.0 %	1,506	100.0 %	2,314	100.0 %	+53.63%

JPY in Million	2022	Weight	2023	Weight	Delta
Netherlands 30.7 %	405	26.9 %	710	30.7 %	+75.40%
Japan 19.8 %	108	7.2 %	459	19.8 %	+323.13%
Australia 16.3 %	510	33.9 %	377	16.3 %	-26.24%
Other 13.6 %	272	18.1 %	316	13.6 %	+16.12%
United States 13.4 %	-	-	310	13.4 %	-
Germany 6.2 %	211	14.0 %	143	6.2 %	-32.21%

Managers	Title	Age	Since
Tomoyuki Arai DFI	Director of Finance/CFO	51	01/08/01
Jun Okada PSD	President	49	01/05/01
Takao Miki BRD	Director/Board Member	47	01/19/01
Satoru Kobayashi BRD	Director/Board Member	43	01/07/01
Toshi Amanuma BRD	Director/Board Member	48	01/19/01

Members of the board	Title	Age	Since
Kazuya Shimamura BRD	Director/Board Member	51	01/08/01
Jun Okada PSD	President	49	01/05/01
Keiji Nagano CHM	Chairman	69	19/04/19
Tomoyuki Arai DFI	Director of Finance/CFO	51	01/08/01
Toshi Amanuma BRD	Director/Board Member	48	01/19/01
Satoru Kobayashi BRD	Director/Board Member	43	01/07/01
Takao Miki BRD	Director/Board Member	47	01/19/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	79,350,709	72,589,663 ( 91.48 %)	246 ( 0.000310 %)	91.48 %

Name	Equities	%	Valuation
Keiji Nagano 2.342 %	1,858,100	2.342 %	2 M ¥
Yoshimi Yamada 2.099 %	1,665,300	2.099 %	1 M ¥
Shoji Matsumoto 0.9584 %	760,500	0.9584 %	633 139 ¥
Sanwa Fudosan KK 0.8846 %	701,900	0.8846 %	584 353 ¥
FUSO PHARMACEUTICAL INDUSTRIES,LTD. 0.8065 %	640,000	0.8065 %	532 819 ¥
Yasunori Sasaki 0.7561 %	600,000	0.7561 %	499 518 ¥
Yuta Otsuka 0.6742 %	535,000	0.6742 %	445 404 ¥
Eil, Inc. (Itabashi) 0.5041 %	400,000	0.5041 %	333 012 ¥
Toyohisa Tsuji 0.5007 %	397,300	0.5007 %	330 764 ¥
Masami Nakano 0.4411 %	350,000	0.4411 %	291 386 ¥

Name	Equities	%	Valuation
3-D MATRIX, LTD. 0.00%	200	0.00%	167 $

3-D Matrix Ltd.

Kojimachi HF Building, 7/F 3-2-4 Koji-machi

102-0083, Tokyo

http://www.3d-matrix.co.jp

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
3-D MATRIX, LTD.	-14.29%	60.27M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+45.66%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research